<ul>
	<li>Interstitial Lung Disease (ILD): Occurs in 1.1% of patients. Withhold Erlotinib for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue Erlotinib if ILD is diagnosed.</li>
	<li>Renal Failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold Erlotinib for severe renal toxicity.</li>
	<li>Hepatotoxicity with or without hepatic impairment including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or discontinue Erlotinib for severe or worsening liver tests.</li>
	<li>Gastrointestinal perforations-discontinue Erlotinib.</li>
	<li>Bullous and exfoliative skin disorders-discontinue Erlotinib.</li>
	<li>Myocardial infarction (Ml)/ischemia: The risk of Ml is increased in patients with pancreatic cancer.</li>
</ul>